Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma

SIMPLE SUMMARY: Thymic carcinoma is a rare neoplasm with a poor outcome, and there are no established therapeutic regimens for metastatic or recurrent disease. Immune checkpoint inhibitors (ICIs), such as PD-1/PD-L1 antibodies, are approved in several human cancers, however, ICIs are not approved in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaira, Kyoichi, Imai, Hisao, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959131/
https://www.ncbi.nlm.nih.gov/pubmed/33802298
http://dx.doi.org/10.3390/cancers13051065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959131/
https://www.ncbi.nlm.nih.gov/pubmed/33802298
http://dx.doi.org/10.3390/cancers13051065

Ejemplares similares